Discover open access scientific publications

Search, annotate, share and cite publications

Publications by X. Wu

P2.01-16 Dynamic ctDNA Monitoring Revealed Novel Resistance Mechanisms and Response Predictors of Osimertinib Treatment in East Asian NSCLC Patients

Journal of Thoracic Oncology

English

P2.17-30 Serum Lipoprotein(A) Correlates With the Effect of Endostar Combined With Concurrent Chemoradiotherapy in Patients With Locally Advanced LSCC

Journal of Thoracic Oncology

English

P2.13-46 Comprehensive Investigation of ERBB2 Transmembrane Domain Mutations (V659/G660) in 12,833 Chinese Lung Cancer Patients

Journal of Thoracic Oncology

English

P3.01-68 Early SBRT to the Primary Tumor May Overcome the Icotinib Resistance in Patients With Advanced NSCLC Harboring EGFR Mutations

Journal of Thoracic Oncology

English

P1.03-017 Benzyl Isothiocyanate Induces Protective Autophagy in Human Lung Cancer Cells Through Endoplasmic Reticulum Stress-Mediated Mechanism

Journal of Thoracic Oncology

English

P2.01-18 Differential Molecular Mechanisms Associated With Dramatic and Gradual Progression in NSCLC Patients With Intrathoracic Dissemination

Journal of Thoracic Oncology

English

P2.03-12 EGFR and ERBB2 Germline Mutations in Chinese Lung Cancer Patients and Their Roles in Genetic Susceptibility to Cancer

Journal of Thoracic Oncology

English

MA26.01 Accumulation of Concomitant Mutations Involved in Drug Resistance in the Sequential ALK TKI Treatments of ALK-Positive NSCLC

Journal of Thoracic Oncology

English

P2.01-108 Temporal Heterogeneity of Resistant Mutations in Sequential ALK TKI Treated Lung Cancer Revealed by NGS-Based Liquid Biopsy

Journal of Thoracic Oncology

English

P1.13-24 EGFR-KDD Is Rare and Demonstrates Variable Anti-Tumor Response to Tyrosine Kinase Inhibitors in East Asian NSCLC Population

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by X. Wu

P2.01-16 Dynamic ctDNA Monitoring Revealed Novel Resistance Mechanisms and Response Predictors of Osimertinib Treatment in East Asian NSCLC Patients

P2.17-30 Serum Lipoprotein(A) Correlates With the Effect of Endostar Combined With Concurrent Chemoradiotherapy in Patients With Locally Advanced LSCC

P2.13-46 Comprehensive Investigation of ERBB2 Transmembrane Domain Mutations (V659/G660) in 12,833 Chinese Lung Cancer Patients

P3.01-68 Early SBRT to the Primary Tumor May Overcome the Icotinib Resistance in Patients With Advanced NSCLC Harboring EGFR Mutations

P1.03-017 Benzyl Isothiocyanate Induces Protective Autophagy in Human Lung Cancer Cells Through Endoplasmic Reticulum Stress-Mediated Mechanism

P2.01-18 Differential Molecular Mechanisms Associated With Dramatic and Gradual Progression in NSCLC Patients With Intrathoracic Dissemination

P2.03-12 EGFR and ERBB2 Germline Mutations in Chinese Lung Cancer Patients and Their Roles in Genetic Susceptibility to Cancer

MA26.01 Accumulation of Concomitant Mutations Involved in Drug Resistance in the Sequential ALK TKI Treatments of ALK-Positive NSCLC

P2.01-108 Temporal Heterogeneity of Resistant Mutations in Sequential ALK TKI Treated Lung Cancer Revealed by NGS-Based Liquid Biopsy

P1.13-24 EGFR-KDD Is Rare and Demonstrates Variable Anti-Tumor Response to Tyrosine Kinase Inhibitors in East Asian NSCLC Population